Stock 6821 ASYMCHEM LABORATORIES (TIANJIN) CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Asymchem Laboratories (Tianjin) Co., Ltd. Share Price Hong Kong S.E.

Equities

6821

CNE100004Z06

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:20 26/04/2024 BST 		5-day change 1st Jan Change
63.35 HKD +7.37% Intraday chart for Asymchem Laboratories (Tianjin) Co., Ltd. +9.98% -30.38%
04-26 Nomura Adjusts Asymchem Laboratories’ Price Target to HK$83.94 From HK$90.12 Keeps at Buy MT
04-26 Nomura Adjusts Asymchem Laboratories’ Price Target to 118.48 Yuan From 127.21 Yuan Keeps at Buy MT

Financials

Sales 2024 * 6.45B 891M 6.97B 71.33B Sales 2025 * 7.41B 1.02B 8B 81.87B Capitalization 28.33B 3.91B 30.6B 313B
Net income 2024 * 1.25B 173M 1.35B 13.84B Net income 2025 * 1.47B 203M 1.59B 16.29B EV / Sales 2024 * 3.42 x
Net cash position 2024 * 6.89B 951M 7.44B 76.14B Net cash position 2025 * 7.49B 1.03B 8.09B 82.76B EV / Sales 2025 * 2.81 x
P/E ratio 2024 *
24.3 x
P/E ratio 2025 *
16.6 x
Employees 9,788
Yield 2024 *
0.85%
Yield 2025 *
1.04%
Free-Float 60.56%
More Fundamentals * Assessed data

Chart Asymchem Laboratories (Tianjin) Co., Ltd.

Dynamic Chart

Latest news about Asymchem Laboratories (Tianjin) Co., Ltd.

Nomura Adjusts Asymchem Laboratories’ Price Target to HK$83.94 From HK$90.12 Keeps at Buy MT
Nomura Adjusts Asymchem Laboratories’ Price Target to 118.48 Yuan From 127.21 Yuan Keeps at Buy MT
Asymchem Laboratories Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tranche Update on Asymchem Laboratories Co., Ltd.'s Equity Buyback Plan announced on March 8, 2024. CI
Asymchem Laboratories' Profit Falls 31% as Revenue Drops 24% in 2023 MT
Asymchem Laboratories Co., Ltd. Proposes Final Ordinary Dividend for the Year Ended 31 December 2023 CI
Asymchem Laboratories Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Asymchem Laboratories Completes A-Share Repurchase Program MT
Asymchem Laboratories Co., Ltd. commences an Equity Buyback Plan for CNY 1,200 million worth of its shares, under the authorization approved on February 29,2024. CI
Nomura Adjusts Asymchem Laboratories Tianjin’s Price Target to HK$90.12 From HK$134.59, Keeps at Buy MT
Nomura Adjusts Asymchem Laboratories (Tianjin)’s Price Target to 127.21 Yuan From 189.98 Yuan, Keeps at Buy MT
Asymchem Laboratories Co., Ltd. Appoints Hou Xinyi as an Independent Non-Executive Director, Effective 29 February 2024 CI
Asymchem Laboratories Co., Ltd. Announces Resignation of Wang Qingsong as Independent Non-Executive Director and Committees CI
Asymchem's Shenzhen Shares Jump 7% on 1.2 Billion Yuan Stock Buyback MT
INSTANT VIEW 8-China Evergrande ordered to liquidate by Hong Kong court RE
More news

Analyst Recommendations on Asymchem Laboratories (Tianjin) Co., Ltd.

Nomura Adjusts Asymchem Laboratories’ Price Target to HK$83.94 From HK$90.12 Keeps at Buy MT
Nomura Adjusts Asymchem Laboratories’ Price Target to 118.48 Yuan From 127.21 Yuan Keeps at Buy MT
Nomura Adjusts Asymchem Laboratories Tianjin’s Price Target to HK$90.12 From HK$134.59, Keeps at Buy MT
Nomura Adjusts Asymchem Laboratories (Tianjin)’s Price Target to 127.21 Yuan From 189.98 Yuan, Keeps at Buy MT
Nomura Adjusts Asymchem Laboratories (Tianjin)'s Price Target to HK$134.59 From HK$130.30, Keeps at Buy MT
More recommendations

Press releases Asymchem Laboratories (Tianjin) Co., Ltd.

AUM Biosciences and Asymchem Complete Phase II API Production Campaign of Novel TRK Inhibitor AQ
Asymchem Laboratories Tianjin : An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section PU
Asymchem Laboratories Tianjin : An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section PU
AzurRx BioPharma : Identifies Asymchem as Potential Partner of Choice for MS1819 Phase 3 Clinical Trial Drug Production AQ
More press releases

News in other languages on Asymchem Laboratories (Tianjin) Co., Ltd.

# Morning note : economia e finanza dai giornali
El crudo se recupera y sube un 2% apoyado en menor ansiedad por COVID en China
Borsa: Hong Kong chiude a +5,23%, voci di stop a zero-Covid
Spekulationen über Lockerung der Corona-Maßnahmen in China
Cina : il mondo a caccia di indizi su stato salute economia Pechino
More news

Quotes and Performance

1 day+7.37%
1 week+9.98%
Current month+3.01%
1 month-0.47%
3 months-3.94%
6 months-38.44%
Current year-30.38%
More quotes

Highs and lows

1 week
57.85
Extreme 57.85
63.35
1 month
57.55
Extreme 57.55
65.20
Current year
56.30
Extreme 56.3
91.05
1 year
56.30
Extreme 56.3
123.30
3 years
56.30
Extreme 56.3
277.14
5 years
56.30
Extreme 56.3
277.14
10 years
56.30
Extreme 56.3
277.14
More quotes

Managers and Directors - Asymchem Laboratories (Tianjin) Co., Ltd.

Managers TitleAgeSince
Rui Yang CEO
 Chief Executive Officer 47 31/03/99
Hao Hong CEO
 Chief Executive Officer 68 06/10/98
Elut Hsu PSD
 President - 31/12/96
Members of the board TitleAgeSince
Hao Hong CEO
 Chief Executive Officer 68 06/10/98
Kar Chung Lee BRD
 Director/Board Member 43 15/06/21
Ye Song BRD
 Director/Board Member 63 17/07/11
More insiders

ETFs positioned on Asymchem Laboratories (Tianjin) Co., Ltd.

Name Weight AuM 1st Jan change Investor Rating
LONCAR CHINA BIOPHARMA ETF - DISTRIBUTING - USD ETF Loncar China BioPharma ETF - Distributing - USD
1.74% 4 M€ -27.92%
More ETFs positioned on Asymchem Laboratories (Tianjin) Co., Ltd.

Quotes

Date Price Change Volume
26/04/24 63.35 +7.37% 285,600
25/04/24 59 -0.34% 154,780
24/04/24 59.2 +0.08% 59,636
23/04/24 59.15 -0.59% 60,700
22/04/24 59.5 +3.30% 31,760

Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am

More quotes

Company Profile

Asymchem Laboratories (Tian Jin) Co Ltd is a China-based company mainly engaged in the contract development manufacturing organization (CDMO) of drugs. The Company's main businesses are the process development, amplification and commercialization of chemical drugs. The Company's product categories cover peptides, oligonucleotides, monoclonal antibodies, antibody-conjugated drugs and messenger RNA. The Company is also engaged in the provision of pharmaceutical formulation solutions, biosynthetic solutions and clinical solutions.
Sector
Pharmaceuticals
Calendar
14/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Asymchem Laboratories (Tianjin) Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
80.99 CNY
Average target price
99.88 CNY
Spread / Average Target
+23.32%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002821 Stock
  4. 6821 Stock